<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639805</url>
  </required_header>
  <id_info>
    <org_study_id>K171205J</org_study_id>
    <nct_id>NCT03639805</nct_id>
  </id_info>
  <brief_title>Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis</brief_title>
  <acronym>MUSICODREP</acronym>
  <official_title>Effect of a Music Therapy Program on Vaso-occlusive Crisis Pain in Sickle Cell Disease Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of painful vaso-occlusive crises, the most common manifestation of sickle cell&#xD;
      disease, is notoriously limited. vaso-occlusive crises pain is multifactorial with a&#xD;
      psychological component. The hypothesis is that the music therapy program MUSIC CARE® can&#xD;
      help alleviate severe vaso-occlusive crises pain in synergy with traditional treatment in&#xD;
      sickle cell disease patients. The main objective of this prospective, randomized, open label&#xD;
      study is to test the effect of the music therapy program MUSIC CARE® on daily mean morphine&#xD;
      consumption during the 3 first days of hospitalisation for severe vaso-occlusive crises.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease, the most frequent monogenic disease in France and in the world, is&#xD;
      induced by a mutation in the β-globin chain of hemoglobin with production of hemoglobin S.&#xD;
      The course of the disease is characterized by very painful, for which treatment is&#xD;
      notoriously limited. vaso-occlusive crises pain is multifactorial with biological and&#xD;
      psychological components. A few studies suggest a beneficial effect of relaxation techniques&#xD;
      in the management of Sickle cell disease pain. MUSIC CARE® is a novative music therapy&#xD;
      program which proved efficient in different models of acute or chronic pain. the hypothesis&#xD;
      is that this program can help alleviate severe pain in synergy with traditional treatment in&#xD;
      SS Sickle cell disease patients, via a dual biological and psychological effect. The main&#xD;
      objective of this prospective, randomized, open label study is to test the effect of the&#xD;
      music therapy program MUSIC CARE® on daily mean morphine consumption during the 3 first days&#xD;
      of hospitalisation for severe vaso-occlusive crises in adult SS Sickle cell disease patients.&#xD;
      Secondary outcomes will include mean daily Visual Analogic Scale during the first 3 days of&#xD;
      hospitalization for severe vaso-occlusive crises, acute complications of vaso-occlusive&#xD;
      crises, duration of severe vaso-occlusive crises and of hospitalization, Hospital Anxiety and&#xD;
      Depression Scale.&#xD;
&#xD;
      20 patients will be included in each group for this pilot study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Anticipated">April 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily mean morphine consumption during the first 3 days of hospitalization for severe vaso-occlusive crises</measure>
    <time_frame>End of the third day of hospitalization for severe vaso-occlusive crises</time_frame>
    <description>The total morphine consumption will be calculated for the first 3 days of hospitalization by a doctor, and a mean daily consumption will be calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vaso-occlusive Crisis</condition>
  <arm_group>
    <arm_group_label>non interventional arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Of Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>interventional arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of Care + music therapy program MUSIC CARE®</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Music therapy program MUSIC CARE® + standard care</intervention_name>
    <description>Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.</description>
    <arm_group_label>interventional arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care of vaso-occlusive crises</intervention_name>
    <description>administration of standard care only</description>
    <arm_group_label>non interventional arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years&#xD;
&#xD;
          -  patients with homozygous Sickle Cell Disease (HbSS,or HbSß0) confirmed by laboratory&#xD;
             center&#xD;
&#xD;
          -  hospitalized for severe vaso-occlusive crisis&#xD;
&#xD;
          -  Visual Analogic Scale≥6 at entry&#xD;
&#xD;
          -  able to speak and write French&#xD;
&#xD;
          -  Patient in physical and clinical capacity of consent (signature of the informed&#xD;
             consent of the patient or in the presence of a third party)&#xD;
&#xD;
          -  affiliated to a social insurance; not subject to a legal protection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other hemoglobinopathy&#xD;
&#xD;
          -  pregnancy or post-scriptum (40 days after labor)&#xD;
&#xD;
          -  antecedent of Reflex Epilepsies&#xD;
&#xD;
          -  major hypoacusia&#xD;
&#xD;
          -  Patients already engaged in a therapeutic protocol or in the period of exclusion after&#xD;
             a previous interventional research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvain LE JEUNE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvain LE JEUNE, Dr</last_name>
    <phone>0148955149</phone>
    <phone_ext>33</phone_ext>
    <email>sylvain.le-jeune@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Jacques Mourad, Pr</last_name>
    <phone>0148955141</phone>
    <phone_ext>33</phone_ext>
    <email>jean-jacques.mourad@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Avicenne University Hospital</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain LE JEUNE, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

